Cited 31 times in
Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 민유홍 | - |
dc.contributor.author | 정준원 | - |
dc.date.accessioned | 2017-10-26T06:40:52Z | - |
dc.date.available | 2017-10-26T06:40:52Z | - |
dc.date.issued | 2005 | - |
dc.identifier.issn | 1083-8791 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/151162 | - |
dc.description.abstract | Allogeneic stem cell transplantation (ASCT) has improved the outcome of acute myelogenous leukemia (AML). To further improve the treatment outcome of ASCT in AML, finding a modifiable prognostic factor is mandatory. We evaluated the effect of CD34+ cell dose on survival in allogeneic bone marrow transplantation (BMT) from HLA-matched sibling donors for AML patients in first complete remission (CR1). The 99 patients included in our analysis were classified into high CD34+ cell dose group (CD34+ cells ≥ 2.5 × 106/kg) and low CD34+ cell dose group (CD34+ cells < 2.5 × 106/kg). The high CD34+ cell dose patients had better overall survival (5-year overall survival rate, 75% ± 6% vs 52% ± 9%; P = .01) and leukemia-free survival (5-year leukemia-free survival rate, 70% ± 6% vs 44% ± 9%; P = .04). CD34+ cell dose was the only independent prognostic factor in overall survival and leukemia-free survival. The high CD34+ cell dose group had a lower relapse incidence with a borderline statistical significance (5-year relapse rate, 27% ± 6% vs 50% ± 10%; P = .09). There were no differences in the engraftment of neutrophil and platelet, grade II-IV acute graft-versus-host disease (GVHD), extensive-stage chronic GVHD, and transplant-related mortality between the high and low CD34+ cell dose groups. We confirmed that high CD34+ cell dose favorably affects the outcomes in allogeneic BMT for AML. The effort to attain a high CD34+ cell dose should be pursued during bone marrow harvest in allogeneic BMT for AML in CR1. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Carden Jennings Publishing | - |
dc.relation.isPartOf | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antigens, CD34/analysis* | - |
dc.subject.MESH | Bone Marrow Cells/cytology* | - |
dc.subject.MESH | Bone Marrow Transplantation* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leukemia, Myeloid, Acute*/mortality | - |
dc.subject.MESH | Leukemia, Myeloid, Acute*/therapy | - |
dc.subject.MESH | Leukocyte Count | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Siblings | - |
dc.subject.MESH | Tissue Donors* | - |
dc.subject.MESH | Transplantation, Homologous | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission | - |
dc.type | Article | - |
dc.publisher.location | United States | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Se-Hoon Lee | - |
dc.contributor.googleauthor | Mark H. Lee | - |
dc.contributor.googleauthor | Je-Hwan Lee | - |
dc.contributor.googleauthor | Yoo Hong Min | - |
dc.contributor.googleauthor | Kyoo-Hyung Lee | - |
dc.contributor.googleauthor | June-Won Cheong | - |
dc.contributor.googleauthor | Jeeyun Lee | - |
dc.contributor.googleauthor | Keon Woo Park | - |
dc.contributor.googleauthor | Jung Hun Kang | - |
dc.contributor.googleauthor | Kihyun Kim | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.contributor.googleauthor | Chul Won Jung | - |
dc.contributor.googleauthor | Seong-Jun Choi | - |
dc.contributor.googleauthor | Jung-Hee Lee | - |
dc.contributor.googleauthor | Keunchil Park | - |
dc.identifier.doi | 10.1016/j.bbmt.2004.11.018 | - |
dc.contributor.localId | A01407 | - |
dc.contributor.localId | A03729 | - |
dc.relation.journalcode | J00308 | - |
dc.identifier.eissn | 1523-6536 | - |
dc.identifier.pmid | 15682073 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S1083879104006007 | - |
dc.subject.keyword | Allogeneic BMT | - |
dc.subject.keyword | Acute myelogenous leukemia | - |
dc.subject.keyword | CD34+ cell dose | - |
dc.contributor.alternativeName | Min, Yoo Hong | - |
dc.contributor.alternativeName | Cheong, June Won | - |
dc.citation.volume | 11 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 122 | - |
dc.citation.endPage | 128 | - |
dc.identifier.bibliographicCitation | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, Vol.11(2) : 122-128, 2005 | - |
dc.date.modified | 2017-05-04 | - |
dc.identifier.rimsid | 43497 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.